Despite Weakened Q4 and Year-End Results, Renovis, Inc. (RNVS) Shares Climb
Renovis, Inc. (NASDAQ: RNVS) shares took a steady climb up the charts this week, stopping at $2.57 at the market’s close. Today, the biopharmaceutical company announced its financial results for the fourth quarter and year ended Dec. 31, 2007, posting a decrease in revenues and net loss, while lowering R&D and overhead expenses. Revenue for the fourth quarter and fiscal 2007 was $1.3 million and $9.8 million, respectively, as compared to $2.2 million and $10.4 million for 2006. Focused on the discovery and development of pharmaceuticals for the treatment of neurological and inflammatory diseases, Renovis attributes the change in revenues…